ECSP12012332A - Asociación de inhibidores de la xantina oxidasa y la instatina y su uso - Google Patents

Asociación de inhibidores de la xantina oxidasa y la instatina y su uso

Info

Publication number
ECSP12012332A
ECSP12012332A ECSP12012332A ECSP12012332A EC SP12012332 A ECSP12012332 A EC SP12012332A EC SP12012332 A ECSP12012332 A EC SP12012332A EC SP12012332 A ECSP12012332 A EC SP12012332A
Authority
EC
Ecuador
Prior art keywords
association
inhibitors
instatine
xantina
oxidase
Prior art date
Application number
Other languages
English (en)
Inventor
Sandro Giuliani
Carlo Alberto Maggi
Francesco Melani
Original Assignee
Menarini Int Operations Lu Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42753377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012332(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Menarini Int Operations Lu Sa filed Critical Menarini Int Operations Lu Sa
Publication of ECSP12012332A publication Critical patent/ECSP12012332A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a la asociación de principios activos, a saber de un inhibidor de la xantina oxidasa con uno o más inhibidores de la HMG CoA reductasa, composiciones farmacéuticas que comprende dicho principio activo, para uso en el tratamiento terapéutico humano o veterinario, y métodos para su preparación.
ECSP12012332 2010-05-10 2012-12-10 Asociación de inhibidores de la xantina oxidasa y la instatina y su uso ECSP12012332A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM2010A000232A IT1400311B1 (it) 2010-05-10 2010-05-10 Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.

Publications (1)

Publication Number Publication Date
ECSP12012332A true ECSP12012332A (es) 2013-02-28

Family

ID=42753377

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSP12012331 ECSP12012331A (es) 2010-05-10 2012-12-10 Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso
ECSP12012332 ECSP12012332A (es) 2010-05-10 2012-12-10 Asociación de inhibidores de la xantina oxidasa y la instatina y su uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSP12012331 ECSP12012331A (es) 2010-05-10 2012-12-10 Combinacion de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso

Country Status (24)

Country Link
US (1) US20130131128A1 (es)
EP (1) EP2568982B1 (es)
JP (1) JP2013526503A (es)
KR (1) KR20130101447A (es)
CN (1) CN103037861A (es)
AR (1) AR081376A1 (es)
AU (1) AU2011252151A1 (es)
BR (1) BR112012028887A2 (es)
CA (1) CA2798573A1 (es)
CL (1) CL2012003143A1 (es)
CO (1) CO6640306A2 (es)
EA (1) EA201201528A1 (es)
EC (2) ECSP12012331A (es)
IL (1) IL222927A0 (es)
IT (1) IT1400311B1 (es)
MA (1) MA34297B1 (es)
MX (1) MX2012013054A (es)
NZ (1) NZ603414A (es)
PE (1) PE20130812A1 (es)
PH (1) PH12012502198A1 (es)
SG (1) SG185474A1 (es)
TW (1) TW201206432A (es)
WO (1) WO2011141431A1 (es)
ZA (1) ZA201209295B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3028371B1 (fr) * 2014-11-06 2016-11-18 Bull Sas Procede de surveillance et de controle deportes d'un cluster utilisant un reseau de communication de type infiniband et programme d'ordinateur mettant en oeuvre ce procede
JP2018135278A (ja) * 2017-02-20 2018-08-30 株式会社スタージェン 循環器疾患及び／又はミトコンドリア病の改善用医薬
KR102284764B1 (ko) 2020-07-08 2021-08-04 주식회사 우드메탈 멀티빔구조를 통한 부속의 결속이 용이한 칸막이

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092580T3 (es) 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
CA2566652C (en) 1998-06-19 2008-10-21 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
ATE324890T1 (de) 2000-11-21 2006-06-15 Sankyo Co Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
KR20120058618A (ko) 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
EP1940397A4 (en) * 2005-08-03 2010-01-20 Takeda Pharmaceuticals North A METHOD FOR TREATING HYPERTONIA
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
EP2101761A4 (en) 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS

Also Published As

Publication number Publication date
SG185474A1 (en) 2012-12-28
MX2012013054A (es) 2013-03-05
US20130131128A1 (en) 2013-05-23
KR20130101447A (ko) 2013-09-13
EA201201528A1 (ru) 2013-04-30
EP2568982A1 (en) 2013-03-20
PH12012502198A1 (en) 2013-02-25
CA2798573A1 (en) 2011-11-17
CO6640306A2 (es) 2013-03-22
MA34297B1 (fr) 2013-06-01
PE20130812A1 (es) 2013-08-08
IT1400311B1 (it) 2013-05-24
WO2011141431A1 (en) 2011-11-17
AU2011252151A1 (en) 2012-11-29
IL222927A0 (en) 2012-12-31
ECSP12012331A (es) 2013-02-28
NZ603414A (en) 2014-03-28
ZA201209295B (en) 2013-08-28
ITRM20100232A1 (it) 2011-11-11
CN103037861A (zh) 2013-04-10
JP2013526503A (ja) 2013-06-24
EP2568982B1 (en) 2014-04-02
BR112012028887A2 (pt) 2016-07-26
TW201206432A (en) 2012-02-16
AR081376A1 (es) 2012-08-29
CL2012003143A1 (es) 2013-06-21

Similar Documents

Publication Publication Date Title
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
PH12015500730A1 (en) Inhibitors of histone demethylases
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2012001757A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas.
GB201014391D0 (en) Drug composition and its use in therapy
CR20150044A (es) Formulación transdérmica que contiene inhibidores de cox
BR112012021445B8 (pt) formulação farmacêutica ou neutracêutica, e uso de um agente promotor de biodisponibilidade
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel
ECSP12012332A (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
CR20120617A (es) Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
CR20120618A (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
UY31057A1 (es) Formulaciones de aminoacido n-halogenado que contiene acido alifatico
CL2009001327A1 (es) Compuestos heterociclo derivados de 3-oxoisoindolin-1-carboxamida; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento del dolor.
AR116040A2 (es) Sal tosilato para-toluensulfonato de 4-(6-cloro-3-metil-4,10-dihidro-3h-2,3,4,9-tetraazabenzo[f]azulen-9-carbonil)-2-fluoro-bencilamida del ácido ciclopropancarboxílico
CL2010000752A1 (es) Composicion farmaceutica que comprende un acido carboxilico saturado, un compuesto anti-hongos y un gel penetrante en la piel; y su uso en el tratamiento de onicomicosis.
UA110458C2 (ru) Інгібітори ns5a вгс
CL2007003284A1 (es) Composicion farmaceutica que comprende una asociacion de i) ciclobenzaprina, ii) aceclofenaco y opcionalmente iii) excipientes; y su uso para el tratamiento de enfermedades musculares dolorosas.